Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.42 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12323382 | 0.83 | OPRM1 (0.56) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL679757 | 0.82 | OPRM1 (0.59) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL14213093 | 0.79 | OPRM1 (0.52) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL12104025 | 0.76 | OPRM1 (0.63) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL16565533 | 0.76 | OPRM1 (0.63) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL12227099 | 0.75 | OPRM1 (0.62) | OPRM1KMT2ATET3FBXL19CXXC5 | |
| SCHEMBL681284 | 0.75 | DRD2 (0.45) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL10637222 | 0.73 | OPRM1 (0.50) | OPRM1KMT2AHSD11B1ALDH1A1LMNA | |
| SCHEMBL684695 | 0.73 | OPRM1 (0.67) | OPRM1HSD11B1 | |
| SCHEMBL8225720 | 0.73 | OPRM1 (0.59) | OPRM1KMT2ATET3FBXL19CXXC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | OPRM1 3131/4885KMT2A 2785/4885TET3 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.